GRAPHITE BIO INC (GRPH) Stock Price, Forecast & Analysis
USA - NASDAQ:GRPH - US38870X1046 - Common Stock
GRPH Key Statistics, Chart & Performance
The current stock price of GRPH is 3.18 USD. In the past month the price increased by 4.95%. In the past year, price increased by 29.8%.
GRPH Latest News, Press Relases and Analysis
GRPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.71 | 412.56B | ||
| AMGN | AMGEN INC | 15.7 | 184.88B | ||
| GILD | GILEAD SCIENCES INC | 15.5 | 157.55B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.86 | 110.64B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.04 | 76.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 899.16 | 60.11B | ||
| INSM | INSMED INC | N/A | 42.50B | ||
| NTRA | NATERA INC | N/A | 29.74B | ||
| BIIB | BIOGEN INC | 10.03 | 24.61B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.47B | ||
| INCY | INCYTE CORP | 16.28 | 20.41B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 32.91 | 13.64B |
Related stock screener links
About GRPH
Company Profile
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
Company Info
GRAPHITE BIO INC
611 Gateway Blvd, Suite 120
South San Francisco CALIFORNIA US
CEO: Josh Lehrer
Employees: 120
Phone: 16504840886
GRAPHITE BIO INC / GRPH FAQ
Can you describe the business of GRAPHITE BIO INC?
Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).
What is the current price of GRPH stock?
The current stock price of GRPH is 3.18 USD. The price decreased by -2.75% in the last trading session.
What is the dividend status of GRAPHITE BIO INC?
GRPH does not pay a dividend.
What is the ChartMill rating of GRAPHITE BIO INC stock?
GRPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is GRAPHITE BIO INC (GRPH) expected to grow?
The Revenue of GRAPHITE BIO INC (GRPH) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for GRAPHITE BIO INC?
GRAPHITE BIO INC (GRPH) has a market capitalization of 184.47M USD. This makes GRPH a Micro Cap stock.
GRPH Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GRPH. When comparing the yearly performance of all stocks, GRPH is one of the better performing stocks in the market, outperforming 88.02% of all stocks.
GRPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GRPH. GRPH has a great financial health rating, but its profitability evaluates not so good.
GRPH Financial Highlights
Over the last trailing twelve months GRPH reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS decreased by -18.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.14% | ||
| ROE | -67.9% | ||
| Debt/Equity | 0 |
GRPH Forecast & Estimates
6 analysts have analysed GRPH and the average price target is 7.14 USD. This implies a price increase of 124.53% is expected in the next year compared to the current price of 3.18.
For the next year, analysts expect an EPS growth of 81.37% and a revenue growth -100% for GRPH